The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
The govt has rolled out three schemes for promoting the manufacture of API
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
Subscribe To Our Newsletter & Stay Updated
